Daré Bioscience (DARE): Assessing the Path to the $7.50 Analyst Target

Key Takeaways

• The $7.50 central target is the arithmetic mean of three verified analyst price targets: $12 (H.C. Wainwright), $8 (Maxim Group), and $2 (Ladenburg Thalmann).
• With the stock near $0.64, reaching $7.50 would require a gain of roughly 1,070%, a very large move even by speculative-biotech standards.
• The analyst target range is extraordinarily wide — $2 to $12 — signaling deep disagreement about the company's pipeline value and its odds of survival.
• Supporting factors include a commercialized product, advancing late-stage programs, and analyst Buy ratings tied to revenue inflection.
• The biggest risks are a sub-$1 share price, potential Nasdaq minimum-bid concerns, ongoing dilution, and the company's lack of profitability.
• Explore more on Major News, Today's Price Move, the Forecast, and Earnings pages for Daré Bioscience.
• For broader market scanning, explore Trending AI Robots.

Analyst Price Targets and Consensus View

Three current, individually attributable analyst targets anchor this analysis. H.C. Wainwright's Douglas Tsao reiterated a Buy rating and a $12 target in September 2026. Maxim Group maintains a Buy with an $8 target, most recently reaffirmed in August 2026. Ladenburg Thalmann's Jeffrey Cohen initiated coverage with a Buy and a $2 target in late October 2026. The arithmetic mean of these three figures is $7.33, rounded to $7.50 for readability. The spread — from $2 to $12 — is among the widest in the biotech space and reflects fundamentally different assumptions about how much of the pipeline's value is financeable and commercially realizable.

It is important to note that aggregators show varying consensus figures, and some databases also list a lower $1 target from UBS, which would pull the mean below $6. No single figure should be read as a guarantee; the dispersion itself is the most important signal. Bullish analysts emphasize the commercial ramp of XACIATO and the late-stage potential of Ovaprene and Sildenafil Cream, while more cautious targets reflect the company's constrained balance sheet and financing risk. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how recent momentum compares.

Current Market Position and Path Toward the Target

The stock has traded between roughly $0.62 and $0.69 in recent sessions, down about 67% over the trailing year and near the bottom of a 52-week range of approximately $0.61 to $3.78. From $0.64, reaching $7.50 implies upside of about 1,070%, a very large move. That is not a path built on a modest re-rating; it would require the market to assign the company a fundamentally higher equity value — effectively re-pricing a roughly $13 million market-capitalization business as a multi-hundred-million-dollar one. In practice, such moves in micro-cap biotech tend to hinge on discrete catalysts such as regulatory progress, partnership deals, or a sharp revenue inflection, rather than gradual appreciation.

What Could Support a Move Toward the Target

Several verified factors underpin the bullish case. XACIATO is an approved, commercialized product, and management and analysts have pointed to emerging commercial execution. Ovaprene, a hormone-free monthly contraceptive, is advancing in late-stage development with prior non-dilutive grant funding support. Sildenafil Cream targets female sexual arousal disorder, an indication with no FDA-approved topical treatment and meaningful market opportunity. Analysts covering the name have maintained Buy ratings and forecast that product revenue will begin scaling in 2026, with revenue-growth projections far above the broader market. If commercialization accelerates or a partnership or regulatory milestone materializes, the rationale for a dramatically higher valuation could strengthen.

What Could Prevent the Target From Being Reached

The obstacles are substantial and largely structural. The company is not profitable, and its sub-$1 share price raises the risk of Nasdaq minimum-bid-price compliance issues. Daré Bioscience has historically relied on repeated equity raises, and its share count has grown significantly over time, meaning any re-rating must overcome ongoing dilution. Commercial ramp-up of XACIATO has been gradual, and pipeline programs carry binary clinical and regulatory risk. A capital raise at depressed prices, a pipeline setback, or simply the market's refusal to underwrite unprofitable micro-cap biotech could keep the stock far below $7.50 for an extended period.

Technical Levels and Market Structure

The stock is trading near multi-year lows, with the $0.61 area acting as nearby support and the $1.00 level serving as a major psychological and listing-rule threshold. Above that, the 52-week high near $3.78 represents the first meaningful resistance zone, and $7.50 sits well above all recent trading history, meaning there is no near-term technical path to the target. Any sustained move higher would likely first require reclaiming and holding the $1.00 level.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, and the three targets cited here were issued or reaffirmed between August and October 2026. Investors should watch quarterly results and revenue disclosures, updates on Ovaprene's regulatory path and Sildenafil Cream's Phase 3 program, any partnership or licensing announcements, and the company's cash position and financing activity, since dilution directly affects per-share value. Nasdaq listing-status developments are also critical given the sub-$1 price.

Final Assessment

The $7.50 central target — the average of three Buy-rated analyst targets ranging from $2 to $12 — implies a move of roughly 1,070% from the current price, a very large and statistically uncommon re-rating. The bull case rests on a commercialized product, a late-stage women's health pipeline, and analyst expectations of a 2026 revenue inflection. The bear case rests on a sub-$1 share price, listing-rule risk, persistent dilution, and no current profitability. The extreme spread among targets indicates that even the covering analysts disagree sharply about the company's risk-adjusted value. Whether Daré Bioscience approaches $7.50 will depend less on valuation math and more on execution: real commercial traction, pipeline milestones, and whether the company can fund itself without destroying per-share value.

Using AI for Ongoing Monitoring

In my view, tools like Tickeron’s AI Daily Buy/Sell Signals provide a practical way to track volatile names such as this one. The system continuously scans market conditions and technical patterns to flag potential shifts, which can complement manual review of catalysts and financial updates. I find it helpful for staying on top of momentum changes without having to watch every tick.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume